Use of cephalosporins for prophylaxis and therapy of polymicrobial infection in mice.
Cefoxitin, cefotetan, and cefmetazole were compared in 10-day therapy of intra-abdominal and subcutaneous infections caused by three organisms: Bacteroides fragilis and Bacteroides thetaiotaomicron combined with either Escherichia coli or Staphylococcus aureus. Intra-abdominal infection was caused by B. fragilis plus B. thetaiotaomicron plus E. coli. Therapy was initiated immediately before inoculation or was delayed for 8 h. Mortality was 14 of 30 (47%) for saline-treated mice, and all survivors developed abscesses. Immediate therapy reduced mortality and the percentage of mice with abscesses (in survivors), respectively, to 17 and 20% with cefoxitin, 0 and 13% with cefotetan, and 0 and 17% with cefmetazole, and the numbers of all bacteria were reduced by all the cephalosporins. Delayed therapy reduced mortality and abscess formation, respectively, to 20 and 8% of mice with cefoxitin, 10 and 93% with cefotetan, and 7 and 96% with cefmetazole. B. thetaiotaomicron survived in all abscesses treated with cefotetan and cefmetazole. Subcutaneous abscesses were caused by each organism alone or in combinations of one aerobe (S. aureus or E. coli) and one or two Bacteroides species. Early therapy reduced the numbers of all bacteria independent of their in vitro susceptibility. All agents reduced the number of each Bacteroides species with either E. coli or S. aureus. However, when therapy was delayed, cefotetan and cefmetazole were less effective than cefoxitin against B. thetaiotaomicron. Cefotetan was the most active agent against E. coli, and cefmetazole was the most effective against S. aureus. These data illustrate the efficacy of all tested cephalosporins in the prophylaxis of polymicrobial infections.
Brook
I
I
Naval Medical Research Institute, Bethesda, Maryland 20814-5055.
D000005:Abdomen / Q000382:microbiology; D000038:Abscess / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D001442:Bacteroides Infections / Q000188:drug therapy / Q000517:prevention & control; D001441:Bacteroides fragilis; D015311:Cefmetazole / Q000494:pharmacology* / Q000627:therapeutic use; D015313:Cefotetan / Q000494:pharmacology* / Q000627:therapeutic use; D002440:Cefoxitin / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004926:Escherichia coli; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000517:prevention & control; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000517:prevention & control; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000517:prevention & control; D013211:Staphylococcus aureus
D015311:Cefmetazole; D015313:Cefotetan; D002440:Cefoxitin